HEALTHCARE ROYALTY PARTNERS β Full Portfolio
77 tracked investments Β· listed companies and verified rows first
BiotechHealthtechMedical DevicesLexington, US
Garo Armen(Executive Officer, Director)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)Karen Valentine(Executive Officer)
BoardBrian Corvese(Director)
Co-investorsAdvent Life SciencesGrazia Equity GmbHOberland CapitalCommodore CapitalInvusLigand Pharmaceuticals+1 more
Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients.
BiotechDigital HealthHealthtechCambridge, US
Lawrence G. Miller(Executive Officer, Director)Dennis Molnar(Executive Officer)Barry Wohl(Chief Business Officer)Ketan Mehta(Head of Product and Engineering, Connected Wearables)Ron Farquhar(Director)Gerald Chan(Director)
Co-investorsAlpha Wave GlobalMorningside GroupSectoral Asset Management
BiotechSeattle, US
Marvin L White(Executive Officer, Director)
Co-investorsYorkville Advisors
Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.
BiotechHealthtechMedical DevicesThousand Oaks, US
Co-investorsDag VenturesEcoR1 CapitalKleiner Perkins
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.
BiotechHealthtechMedical DevicesRedwood City, US
Dennis M. Lanfear(Executive Officer, Director)Denny Lanfear(Founder)inAlan C. Herman(Executive Officer)Jean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)
Co-investorsF-Prime CapitalSofinnova VenturesVenrock
Nektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction.
BiotechHealthtechSan Francisco, US
Howard W. Robin(Executive Officer, Director)Gil M. Labrucherie(Executive Officer)Maninder Hora(Executive Officer)Stephen K. Doberstein(Executive Officer)John Nicholson(Executive Officer)Jillian B. Thomsen(Executive Officer)
Co-investorsNew Enterprise Associates (NEA)
BiotechTel Aviv
Shmuel Cabilly(Director)June Almenoff(Executive Officer)Ofer Tsimchi(Director)Rick D Scruggs(Executive Officer, Director)Nicolas Weinstein(Director)Alla Felder(Director)
Co-investorsLifeSci Venture Partners
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)Stephen Garbacz(Executive Officer)
BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)Vikas Goyal(Director)
Co-investorsMRL Ventures FundOUP (Osage University Partners)RA CapitalAlphabetAtlas Venture
The site presents ADYNOVATE, a PEGylated recombinant antihemophilic Factor VIII injectable used to treat and control bleeding in adults and children with hemophilia A.
BiotechHealthtech
A biopharmaceutical company (Ipsen, following its acquisition of Albireo Pharma) developing and commercializing medicines in oncology, rare diseases, and neuroscience for patients with high unmet medical needs.
BiotechHealthtech
Co-investorsDecheng Capital
Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs.
BiotechFremont, US
Michael Raab(Executive Officer, Director)Mark Kaufmann(Executive Officer)Elizabeth Grammer(Executive Officer)David Rosenbaum(Executive Officer)Jeremy Caldwell(Executive Officer)Mike Raabin
Co-investorsForesite CapitalNew Enterprise Associates (NEA)
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.
BiotechHealthtech
Co-investorsAisling CapitalAmzak HealthEcoR1 CapitalFrazier Life SciencesLongwood FundSequoia Capital
BiotechNewton Centre, US
Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)
BoardScott Minick(Director)Todd T. Foley(Director)inVincent Miles(Director)Ansbert K. Gadicke(Director)in
Co-investorsSofinnova VenturesMPM BioImpact
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology.
BiotechHealthtechMedical DevicesAlpharetta, US
Charles Deignan(Executive Officer)Glenn Noronha(Executive Officer)Daniel H. White(Executive Officer, Director)Christy Shaffer(Director)Clay Thorp(Director)Mark Prausnitz(Director)
Co-investorsMountain Group CapitalSolasta VenturesHatterasHatteras Venture Partners
Curis is a biopharmaceutical company developing therapeutics for cancer treatment, with a pipeline targeting hematologic malignancies and other cancers through drug candidates such as its lead IRAK4 inhibitor.
BiotechHealthtech
EBVALLO is an on-demand allogeneic T-cell immunotherapy approved to treat relapsed or refractory EBV-positive post-transplant lymphoproliferative disease (PTLD) in patients whose disease has failed rituximab with or without chemotherapy.
BiotechDigital Health
ELIGARD is an androgen deprivation therapy used to lower testosterone levels, which may slow the growth of prostate cancer.
BiotechHealthtech
IQIRVO is a prescription medicine for treating primary biliary cholangitis (PBC) in adults, used with ursodeoxycholic acid (UDCA) or alone for patients who cannot tolerate UDCA.
BiotechHealthtech
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.
BiotechHealthtechNewton, US
Stuart Poulton(Executive Officer)Michael Mano(Executive Officer)Reshma Rangwala(Executive Officer)Richard Paulson(Executive Officer, Director)Stephen Mitchener(Executive Officer)Michael Mason(Executive Officer)
Co-investorsAvoro Capital AdvisorsForesite Capital
KORSUVA is an FDA-approved prescription medicine that treats moderate-to-severe chronic kidney disease-associated pruritus (itching) in adults undergoing hemodialysis.
BiotechDigital Health
Lantheus is a radiopharmaceutical company that develops and delivers diagnostic imaging and therapeutic products used to detect, treat, and monitor disease.
BiotechHealthtechMedical Devices
Nanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients.
BiotechDeep TechMedical Devices
Co-investorsKarista
OPKO Health is an integrated healthcare and pharmaceutical company that develops diagnostics and therapies for serious diseases, working with partner pharmaceutical firms across global markets.
BiotechHealthtechMedical Devices
Orenitram is a prescription oral medication containing treprostinil, indicated to treat pulmonary arterial hypertension (PAH) by slowing disease progression and improving exercise capacity in adults.
BiotechHealthtech
Co-investorsSofinnova Ventures
REGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies.
BiotechHealthtechRockville, US
Kenneth T. Mills(Executive Officer, Director)
BoardJohn Daniel Kiser(Director)Allan M. Fox(Director)Benjamin Auspitz(Director)Donald J. Hayden, Jr.(Director)
Co-investorsF-Prime CapitalVenrock
RELISTOR is an FDA-approved prescription medication specifically designed to treat opioid-induced constipation (OIC) by targeting the constipating effect of opioids in the gut without affecting central pain relief.
BiotechDigital Health
Co-investors5AM Ventures
Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.
BiotechHealthtechBoston, US
Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)
BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inNeil Exter(Director)inTodd Foley(Director)
Co-investorsForesite CapitalNew Enterprise Associates (NEA)Pfizer Venture InvestmentsOrbiMedThird Rock Ventures
SEYSARA is a prescription medication with a patient co-pay assistance program (Almirall Advantage) that offers savings on retail and network pharmacy purchases.
BiotechHealthtech
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, starting with SP001, a third-generation anti-CD40L antibody for IgG4-related disease.
BiotechHealthtech
IBSRELA is a prescription medicine (tenapanor) from Ardelyx used in adults to treat irritable bowel syndrome with constipation (IBS-C), relieving constipation and abdominal pain.
BiotechHealthtech
TG Therapeutics is a biopharmaceutical company developing and marketing treatments for relapsing forms of multiple sclerosis.
Biotech
Theravance develops medicines for specialty respiratory conditions, focusing on serious lung diseases.
Biotech
TRELEGY is a once-daily prescription inhaler used long-term to treat COPD (including chronic bronchitis and emphysema) and asthma in adults.
Biotech
uniQure is a gene therapy company developing treatments for Huntington's disease and other serious medical conditions.
BiotechHealthtech
Matthew Kapustain
Co-investorsAdvent Life SciencesForesite Capital
Vafseo (vadadustat) is a once-daily oral prescription medicine that treats anemia caused by chronic kidney disease in adults who have been on dialysis for at least three months.
BiotechHealthtech
Zevra is a rare-disease pharmaceutical company that develops and delivers therapies for patients with rare diseases, such as Niemann-Pick disease type C, and their care partners.
BiotechHealthtech
ZOLGENSMA is a one-time gene replacement therapy for treating spinal muscular atrophy (SMA) in children under 2 years old, aiming to stop disease progression and support developmental milestones such as sitting, standing, and walking.
BiotechDigital HealthHealthtech
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.